A study to determine plasma antioxidant concentrations in patients with Barrett’s oesophagus

D M Clements, D A Oleesky, S C Smith, H Wheatley, D A Hullin, T J Havard, D J Bowrey


Background: Dietary questionnaire studies have suggested that patients with oesophageal adenocarcinoma are deficient in antioxidants. It is not known whether the same holds true for patients with the precursor lesion, Barrett’s oesophagus.

Aims: To evaluate the hypothesis that patients with Barrett’s oesophagus are deficient in antioxidants compared with patients without evidence of Barrett’s oesophagus.

Patients and methods: Plasma antioxidant profiles (copper, selenium, zinc; vitamins A, C, and E; carotenoids) were determined for patients with Barrett’s oesophagus (n = 36), patients with erosive oesophagitis (n = 32), and patient controls (n = 35).

Results: Patients with Barrett’s oesophagus had significantly lower plasma concentrations of selenium, vitamin C, β-carotene, and xanthophyll compared with the other groups.

Conclusions: This study confirms the hypothesis that patients with Barrett’s oesophagus are deficient in certain antioxidants.

PATIENTS AND METHODS
Plasma antioxidant profiles were determined for a prospectively enrolled cohort of subjects attending the endoscopy suite at the Royal Glamorgan Hospital, Llantrisant, UK, during the period May to September 2003. Our study was approved by the Bro-Taf local research ethics committee (protocol 03/5011) and the Royal Glamorgan Hospital research and development board. Each patient provided written informed consent for venepuncture.

Because antioxidants may act as reverse acute phase reactants, patients with occult inflammatory processes were excluded on the basis of either a raised C reactive protein concentration (> 10 mg/litre) or hypoalbuminaemia (< 32 g/litre). Additional exclusion criteria were the presence of gastroduodenal ulceration and a history of pancreatitis or previous foregut surgery, other than cholecystectomy.

Patients were divided into the following study groups:
(1) 36 patients (33 men, three women) with Barrett’s oesophagus (defined by endoscopic columnar lined oesophagus and intestinal metaplasia on biopsy), mean age 57 years (range, 39–85);
(2) 32 patients (20 men, 12 women) with Los Angeles grade B or C erosive oesophagitis, mean age 59 years (range, 35–77);
(3) 35 patient controls (15 men, 20 women) free of reflux symptoms who had normal endoscopic appearances in the oesophagus, stomach, and duodenum, mean age 49 years (range, 20–72).

Sample size determination
In a previous study, we identified significant differences in the antioxidant concentrations between patients with chronic pancreatitis and healthy control subjects, and the magnitude of the differences was in excess of one standard deviation. For our current study, we assumed that the magnitude of the differences between Barrett’s and control patients would be more modest, in the order of 0.75 standard deviations. Assuming a significance concentration of 5% and a power of 80%, equal groups of 30 patients would be required.

Assay details
The biochemical parameters assessed were plasma concentrations of:
• the trace elements copper, selenium and zinc;
• vitamins A, C, and E;
therefore, it is possible that antioxidant supplementation could reduce the mortality risk for glandular dysplasia and adenocarcinoma in these patients and appropriate studies are needed to explore this issue.

"Antioxidants are central to the cellular defence mechanism against oxidative damage."

Our current study has taken the investigation one step further back in an attempt to elucidate potential differences in antioxidant concentrations between patients with reflux, with and without Barrett’s oesophagus. Antioxidants are inventories were completed by patients and antioxidant intake calculated based upon the known content of each food substance. These reports suggested a protective effect for diets rich in citrus fruits, certain vegetables, and several antioxidants, notably β-carotene and vitamin C.

Two studies from the same institution of patients with Barrett’s oesophagus identified low selenium concentrations as a risk factor for progression to adenocarcinoma. Rudolph et al. evaluated selenium concentrations in patients with Barrett’s oesophagus enrolled in a surveillance programme. They found that low selenium concentrations were associated with an increased risk of progression to high grade dysplasia, loss of wild-type p53, and aneuploidy. No association was seen between low selenium concentrations and loss of the wild-type p16 gene, an early event in carcinogenesis, leading the authors to speculate that low selenium concentrations are a late event in the development of oesophageal adenocarcinoma.

A recent Cochrane review examining the potential role of antioxidant supplementation in the prevention of gastrointestinal malignancy found no evidence of a protective effect, with the exception of a modest benefit for selenium. It should be stressed that the study groups were heterogeneous and included patients with hepatocellular, colorectal, oesophageal, gastric, and pancreatic cancers.

Antioxidants are central to the cellular defence mechanism against oxidative damage.

Table 1 Trace element concentrations

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Barrett’s oesophagus (n = 36)</th>
<th>Erosive oesophagitis (n = 32)</th>
<th>Patient controls (n = 35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copper (μmol/l)</td>
<td>16.0 (15.0 to 16.9)</td>
<td>16.9 (15.5 to 18.3)</td>
<td>16.3 (14.9 to 17.7)</td>
</tr>
<tr>
<td>Selenium (μmol/l)</td>
<td>0.72* (0.67 to 0.78)</td>
<td>0.75 (0.71 to 0.79)</td>
<td>0.81 (0.74 to 0.87)</td>
</tr>
<tr>
<td>Zinc (μmol/l)</td>
<td>13.3 (11.4 to 15.1)</td>
<td>12.9 (12.2 to 13.5)</td>
<td>13.1 (11.6 to 14.6)</td>
</tr>
</tbody>
</table>

Values shown are mean (95% confidence interval). *p = 0.05 v patient controls.

Table 2 Vitamin concentrations

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Barrett’s oesophagus (n = 36)</th>
<th>Erosive oesophagitis (n = 32)</th>
<th>Patient controls (n = 35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin A (μmol/l)</td>
<td>2.17 (1.97 to 2.38)</td>
<td>2.01 (1.82 to 2.21)</td>
<td>1.97 (1.83 to 2.11)</td>
</tr>
<tr>
<td>Vitamin C (μmol/l)</td>
<td>18.3* (13.2 to 23.4)</td>
<td>26.6 (19.6 to 33.6)</td>
<td>27.1 (21.4 to 32.7)</td>
</tr>
<tr>
<td>Vitamin E (μmol/l)</td>
<td>26.7 (23.0 to 30.4)</td>
<td>29.1 (25.6 to 32.6)</td>
<td>28.3 (25.1 to 31.4)</td>
</tr>
</tbody>
</table>

Values shown are mean (95% confidence interval). *p = 0.02 v patient controls and p = 0.05 v erosive oesophagitis.

- the carotenoids (α-carotene, β-carotene, β-cryptoxanthine, lycopene, and xanthophyll).

Venous blood was collected from each subject after a six hour fast (immediately before endoscopy). Samples for trace element analysis were collected in trace element free sodium heparin Vacutainers (Becton Dickinson, Le Pont de Claux, France); those for vitamin analysis were taken into lithium heparin Vacutainers (Becton Dickinson) and transported to the laboratory in a light excluding container. All samples were centrifuged within 30 minutes of collection; separated plasma was divided into aliquots and stored in a −70°C freezer.

Samples were subsequently analysed in batches in the medical biochemistry department, University Hospital of Wales, Cardiff, UK. Copper and zinc were measured using flame atomic absorption on an FS-220 spectrophotometer (Varian Inc, Lexington, Massachusetts, USA). Selenium was measured by electrothermal graphite furnace atomic absorption on an AA-600 spectrophotometer (Varian Inc, Lexington, Massachusetts, USA). Vitamins A, C, and E and the carotenoids were measured by means of high performance liquid chromatography with spectrophotometric detection.

Continuous data were compared using the unpaired t test, with significance assumed at the 5% level.

RESULTS

Tables 1–3 summarise the antioxidant profiles. Patients with Barrett’s oesophagus had significantly lower plasma concentrations of selenium, vitamin C, β-cryptoxanthine, and xanthophyll compared with the other groups.

DISCUSSION

It is unclear why some patients with gastro-oesophageal reflux disease develop Barrett’s oesophagus. Physiological oesophageal studies have shown that Barrett’s oesophagus is closely linked to poor lower oesophageal barrier function, hiatus hernia, and high levels of oesophageal acid (and bile) exposure. Nonetheless, even for similar oesophageal reflux exposure, end organ manifestations vary between individuals; genetic factors may be implicated. Our current study evaluated whether or not antioxidants could influence the development of Barrett’s oesophagus.

There are few publications on antioxidants in patients with Barrett’s oesophagus. However, several studies have evaluated antioxidant intakes in patients with oesophageal adenocarcinoma using dietary questionnaires. It is possible that antioxidant supplementation could reduce the mortality risk for glandular dysplasia and adenocarcinoma in these patients and appropriate studies are needed to explore this issue.
central to the cellular defence mechanism against oxidative damage—they catalyse the breakdown of hydrogen peroxide and fatty acyl lipid peroxides, in the presence of reduced glutathione, to water and the corresponding alcohols. Such peroxides are a source of potentially damaging free radicals, which can cause peroxidation of polyunsaturated fatty acids in the cell membrane. The toxic oxygen derivatives, which are neutralised by the antioxidants, are produced by normal cellular metabolic activity and by a variety of injurious agents. 3

Our main findings were that patients with Barrett’s oesophagus had significantly lower plasma concentrations of the antioxidants selenium, vitamin C, β-cryptoxanthine, and xanthophyll compared with patient controls. What is the therapeutic potential of these observations? More information is available on squamous dysplasia and neoplasia, notably from China. The epidemiology of squamous carcinoma in high incidence regions of China (Linxian province) supports an association with antioxidant deficiency. 4 Large scale antioxidant supplementation studies in this region revealed modest reductions in the mortality risk from oesophageal or gastric cardia malignancy. 5 It is an appealing concept that the same will hold true for glandular dysplasia and adenocarcinoma.

Table 3 Carotenoid concentrations

<table>
<thead>
<tr>
<th></th>
<th>Barrett’s oesophagus (n = 36)</th>
<th>Erosive oesophagitis (n = 32)</th>
<th>Patient controls (n = 35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>α Carotene (µmol/l)</td>
<td>0.05 (0.04–0.06)</td>
<td>0.05 (0.04–0.06)</td>
<td>0.05 (0.04–0.06)</td>
</tr>
<tr>
<td>β Carotene (µmol/l)</td>
<td>0.28 (0.24–0.32)</td>
<td>0.30 (0.26–0.34)</td>
<td>0.32 (0.27–0.37)</td>
</tr>
<tr>
<td>β Cryptoxanthine (µmol/l)</td>
<td>0.06 (0.05–0.08)</td>
<td>0.10 (0.08–0.13)</td>
<td>0.08 (0.07–0.10)</td>
</tr>
<tr>
<td>Lycopene (µmol/l)</td>
<td>0.32 (0.26–0.38)</td>
<td>0.28 (0.20–0.35)</td>
<td>0.26 (0.21–0.31)</td>
</tr>
<tr>
<td>Xanthophyll (µmol/l)</td>
<td>0.35* (0.27–0.44)</td>
<td>0.55 (0.41–0.69)</td>
<td>0.48 (0.33–0.63)</td>
</tr>
</tbody>
</table>

Values shown are mean (95% confidence interval).

*p = 0.008 v oesophagitis; **p = 0.002 v oesophagitis.


